Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens

Background: Previous phase II trials in Japan suggested that irinotecan was a promising agent for advanced or metastatic breast cancer pretreated with anthracycline. However, irinotecan has not yet been evaluated in the salva ge setting for breast cancer pretreated with both anthracycline and taxane, which are two active agents for breast cancer. Methods: The efficacy and safety of irinotecan were retrospectively evaluat ed in patients with breast cancer who had previously been treated with both doxorubicin and docetaxel. From 1996 to 1999, irinotecan was administered to 20 patients, all with a performance status of <2. Irinotecan treatment w as repeated in similar to6 week cycles consisting of the administration of irinotecan once weekly for 4 weeks followed by a 2 week rest. The median do se of irinotecan administered was 100 mg/m(2) weekly. The median number of irinotecan cycles given was 1 (range: 1-8 cycles). The median total dose wa s 388 mg/m(2) (range: 50-2400 mg/m(2)). Results: Performance status declined to >3 after treatment with irinotecan in four patients. Two patients had grade 3 leukopenia; three had grade 3 an emia and one had a creatinine elevation of grade 4. The objective response rate for all patients was 5.0% (95% Cl: 0-15.5%). The median time to progre ssion and overall survival were 35 days (range: 17-285 days) and 124 days ( range: 17-667 days), respectively, since the start of the administration of irinotecan. Conclusions: Salvage chemotherapy with irinotecan may be inactive against a dvanced and metastatic breast cancer pretreated wi th doxorubicin and docet axel. We will evaluate irinotecan for advanced and metastatic breast cancer patients as first- or second-line chemotherapy combined with anthracycline or taxane.